InMed Reports Second Quarter Fiscal 2023 Financial Results

Closed calendar year 2022 with strong cash position of $11.5 millionApproaches completion of enrollment for Ph 2 clinical trial in EBAdvances research...

Related Keywords

United Kingdom ,Vancouver ,British Columbia ,Canada ,British ,Erica Adams , ,Glaucoma Program ,Company Nasdaq ,Development Programs ,Neurodegenerative Diseases Program ,Inmed Pharmaceuticals Inc ,Med Pharmaceuticals ,Epidermolysis Bullosa ,Neurodegenerative Diseases ,Condensed Consolidated Interim Balance Sheets ,Condensed Consolidated Interim Statements ,Nasdaq Inm ,Nmed Pharmaceuticals Inc ,